Read by QxMD icon Read

immunohistochemical analysis of carbonic anhydrase 9 in renal cell carcinoma

Shijie Liu, Zuhong Tian, Lei Zhang, Shuang Hou, Sijun Hu, Junshen Wu, Yuming Jing, Huimin Sun, Fei Yu, Libo Zhao, Ruoxiang Wang, Hsian-Rong Tseng, Haiyen E Zhau, Leland W K Chung, Kaichun Wu, Hao Wang, Jason Boyang Wu, Yongzhan Nie, Chen Shao
Circulating tumor cells (CTCs) have emerged as promising tools for noninvasive cancer detection and prognosis. Most conventional approaches for capturing CTCs use an EpCAM-based enrichment strategy, which does not work well in cancers that show low or no expression of EpCAM, such as renal cell carcinoma (RCC). In this study, we developed a new set of cell surface markers including CA9 and CD147 as alternative CTC-capture antigens specifically designed for RCC patients. We showed that the expression of both CA9 and CD147 was prevalent in a RCC patient cohort (n=70) by immunohistochemical analysis, with both molecules in combination covering 97...
September 13, 2016: Oncotarget
Inkeun Park, Yong Mee Cho, Jae-Lyun Lee, Jin-Hee Ahn, Dae-Ho Lee
In metastatic renal cell carcinoma (mRCC), the prognostic role of several tumor tissue biomarkers has been evaluated, but the results were controversial. This study aims to verify the prognostic importance of selected tumor tissue biomarkers in patients with mRCC. The clinicopathological features, immunohistochemical staining and scoring for select tissue biomarkers, treatment, and outcome of patients with mRCC treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) between July 2006 and March 2011 at Asan Medical Center in Seoul, South Korea, were reviewed...
April 2016: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
Andrea Soltysova, Jan Breza, Martina Takacova, Jana Feruszova, Sona Hudecova, Barbora Novotna, Eva Rozborilova, Silvia Pastorekova, Ludevit Kadasi, Olga Krizanova
Clear cell renal cell carcinoma (ccRCC) is the most frequent type of kidney cancer. In order to better understand the biology of ccRCC, we accomplished the gene profiling of fresh tissue specimens from 11 patients with the renal tumors (9 ccRCCs, 1 oncocytoma and 1 renal B-lymphoma), in which the tumor-related data were compared to the paired healthy kidney tissues from the same patients. All ccRCCs exhibited a considerably elevated transcription of the gene coding for carbonic anhydrase IX (CAIX). Moreover, the ccRCC tumors consistently displayed increased expression of genes encoding the glycolytic pathway enzymes, e...
July 2015: International Journal of Oncology
Kvetoslava Peckova, Petr Grossmann, Stela Bulimbasic, Maris Sperga, Delia Perez Montiel, Ondrej Daum, Pavla Rotterova, Bohuslava Kokoskova, Pavla Vesela, Kristyna Pivovarcikova, Kevin Bauleth, Jindrich Branzovsky, Magdalena Dubova, Milan Hora, Michal Michal, Ondrej Hes
UNLABELLED: Renal cell carcinoma (RCC) with leiomyomatous stroma (RCCLS) is a recently recognized entity with indolent biological behavior. The diagnostic implication of absence/presence of VHL gene mutation, VHL hypermethylation, or/and loss of heterozygosity of chromosome 3p (LOH 3p) is widely discussed. Criteria for establishing a diagnosis of RCCLS are still lacking. Fifteen RCCLSs were retrieved from our registry. The cases were studied with consideration to the morphology, immunohistochemistry, and molecular genetics...
October 2014: Annals of Diagnostic Pathology
E Jason Abel, Tyler M Bauman, Madelyn Weiker, Fangfang Shi, Tracy M Downs, David F Jarrard, Wei Huang
The objective of this study was to compare the predictive ability of potential tissue biomarkers to known prognostic factors that predict renal cell carcinoma (RCC) recurrence using an automated system of immunohistochemical analysis. After institutional review board approval, a tissue microarray was constructed using tissue from patients who had partial or radical nephrectomy for RCC. Patients with metastatic disease were excluded. Immunohistochemical staining of the tissue microarray for Ki-67, C-reactive protein, carbonic anhydrase 9, and hypoxia-inducible factors 1α and 2α was analyzed using automated image analysis...
May 2014: Human Pathology
Constantijn H J Muselaers, Alexander B Stillebroer, Ingrid M E Desar, Marye J Boers-Sonderen, Carla M L van Herpen, Mirjam C A de Weijert, Johan F Langenhuijsen, Egbert Oosterwijk, William P J Leenders, Otto C Boerman, Peter F A Mulders, Wim J G Oyen
UNLABELLED: Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of metastatic clear cell renal cell carcinoma (RCC). Although TKIs have demonstrated good clinical efficacy, the lack of complete responses, the chronic nature of the treatment, and the side effects are clear disadvantages. An interesting new approach in the treatment of clear cell RCC is antibody-mediated therapy with the chimeric anti-carbonic anhydrase IX (CAIX) antibody girentuximab (cG250). As the results of several girentuximab trials become available, the question arises of whether TKI treatment can be combined with girentuximab-based therapy...
February 2014: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Juana Dornbusch, Aristeidis Zacharis, Matthias Meinhardt, Kati Erdmann, Ingmar Wolff, Michael Froehner, Manfred P Wirth, Stefan Zastrow, Susanne Fuessel
BACKGROUND: Patients with metastatic clear cell renal cell carcinoma (ccRCC) are frequently treated with tyrosine kinase inhibitors (TKI) such as sunitinib. It inhibits angiogenic pathways by mainly targeting the receptors of VEGF and PDGF. In ccRCC, angiogenesis is characterized by the inactivation of the von Hippel-Lindau gene (VHL) which in turn leads to the induction of HIF1α target genes such as CA9 and VEGF. Furthermore, the angiogenic phenotype of ccRCC is also reflected by endothelial markers (CD31, CD34) or other tumor-promoting factors like Ki67 or survivin...
2013: PloS One
Yuhei Kondo, Kazuhiro Yoshikawa, Yukinobu Omura, Atsushi Shinohara, Yoshiaki Kazaoka, Junji Sano, Yoshimi Mizuno, Toyoharu Yokoi, Shiro Yamada
Carbonic anhydrase 9 (CA9) is a glycoprotein present on the surface of cell membranes. It is expressed in 90% of renal cancer cells, but not in normal kidney tissue. Immunotherapy targeting CA9 is underway, and our group has also conducted a clinical trial using CA9 as a cancer vaccine and confirmed the induction of cytotoxic T lymphocytes, with efficacy in some cases. Expression of CA9 antigen in oral cancer has not been reported in Japan, but our results indicate that immunotherapy targeting CA9 might be possible...
May 2011: Oncology Reports
Adriana von Teichman, Eva Compérat, Silvia Behnke, Martina Storz, Holger Moch, Peter Schraml
Multilocular cystic renal cell carcinoma is a rare renal cell carcinoma with an excellent prognosis. To clarify the relationship with typical clear cell renal cell carcinoma, we evaluated 15 cases of multilocular cystic renal cell carcinomas diagnosed according to the 2004 WHO classification. Von Hippel Lindau (VHL) gene mutations were determined by whole genome amplification and direct sequencing. Carbonic anhydrase 9 (CAIX), a hypoxia-inducible factor (HIF) target, paired box gene 2 (PAX2), cyclin-dependent kinase inhibitor p27 and glycogen synthase kinase 3-β (GSK3β) were immunohistochemically evaluated as members of the VHL protein (pVHL)- and phosphatase and tensin homolog (PTEN)-controlled pathways...
April 2011: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
Hakan Aydin, Longwen Chen, Liang Cheng, Susan Vaziri, Huiying He, Ram Ganapathi, Brett Delahunt, Cristina Magi-Galluzzi, Ming Zhou
Recently several low-grade renal cell tumors, distinct from those recognized by the 2004 World Health Organization classification of renal tumors, have been described. These tumors had similar clinicopathologic features, being low-stage tumors with cystic, tubuloacinar, and/or papillary architecture. The tumor cells were low grade with variable amounts of clear cytoplasm that was positive for cytokeratin 7 (CK7), but negative for CD10. Genetic changes characteristic of clear cell or papillary renal cell carcinoma were not seen in these tumors...
November 2010: American Journal of Surgical Pathology
Matthew H T Bui, Harri Visapaa, David Seligson, Hyung Kim, Ken-Ryu Han, Yunda Huang, Steve Horvath, Eric J Stanbridge, Aarno Palotie, Robert A Figlin, Arie S Belldegrun
PURPOSE: The natural history of renal cell carcinoma (RCC) is complex and not entirely explained by conventional prognostic factors. In this study we evaluated the prognostic value of carbonic anhydrase IX (CAIX) and Ki67 to predict survival in RCC. MATERIALS AND METHODS: Immunohistochemical analysis using a CAIX and a Ki67 monoclonal antibody was performed on tissue microarrays constructed from paraffin embedded specimens from 224 patients treated with nephrectomy for clear cell renal carcinoma...
June 2004: Journal of Urology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"